A poster presented at ENDO 2021 appears to show promise for a new treatment aimed at patients with Cushing’s syndrome. The poster, presented by Strongbridge Biopharma, plc, a global commercial-stage biopharmaceutical company, announced that detailed results from the previously reported Phase 3 LOGICS study of RECORLEV® (levoketoconazole) in patients with endogenous Cushing’s syndrome were presented […]
